[1] Matsuda M, Seki E. Hepaticstellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis. Semin Liver Dis, 2020, 40(3): 307-320. [2] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. [3] Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology, 2022, 75(2): 473-488. [4] Kalluri R, Lebleu VS. The biology, function, and biomedical applications of exosomes. Science, 2020, 367(6478):1232-1238. [5] Dai M, Yu M, Zhang Y, et al. Exosome-like vesicles derived from adipose tissue provide biochemical cues for adipose tissue regeneration. Tissue Eng Part A, 2017, 23(21-22): 1221-1230. [6] Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev, 2013, 22(6): 845-854. [7] Tan CY, Lai RC, Wong W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther, 2014, 5(3): 76. [8] Zhang S, Chu WC, Lai RC, et al. Exosomes derived from human embryonic mesenchymal stem cells promote osteochondral regeneration. Osteoarthritis Cartilage, 2016, 24(12): 2135-2140. [9] Hu GW, Li Q, Niu X, et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res Ther, 2015, 6: 10. [10] Abbaszadeh H, Ghorbani F, DerakhshanI M, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm. J Cell Physiol, 2020, 235(2): 706-717. [11] Wang C, Li Z, Liu Y, et al. Exosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets. Theranostics, 2021, 11(8): 3996-4010. [12] Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med, 2019, 65: 37-55. [13] Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet, 2021, 398(10308): 1359-1376. [14] Schuppan D, Ashfaq-khan M, Yang AT, et al. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol, 2018, 68-69: 435-451. [15] 郭悦承,陆伦根.肝纤维化临床诊断与治疗研究进展.实用肝胆病杂志,2022,25(3):305-308. [16] Xu L, Hui AY, Albanis E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut, 2005, 54(1): 142-151. [17] 郝书理,张纪元,金磊,等.酒精性肝病患者血浆白细胞介素-21水平及重组IL-21对LX-2肝星状细胞增殖和活化的影响.实用肝脏病杂志,2014,17(1):18-21. [18] Carson JP, Robinson MW, Ramm GA, et al. RNA sequencing of LX-2 cells treated with TGF-beta1 identifies genes associated with hepatic stellate cell activation. Mol Biol Rep, 2021, 48(12): 7677-7688. [19] Benov L. Improvedformazan dissolution for bacterial MTT assay. Microbiol Spectr, 2021, 9(3): e0163721. [20] Park HS, Song JW, Park JH, et al. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy, 2021, 17(9): 2549-2564. |